NP / PA
Travis, Courtney
Travis, Courtney was paid $289K by Medicaid between Aug 2018 and Jan 2021, across 20 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 51% of everything it billed.
33Billing provider infoTRAVIS, COURTNEY
KNOXVILLE, TN 37909
KNOXVILLE, TN 37909
33aNPI1376910166assigned 08/27/2015
33bProvider typeFamily Nurse Practitioner
28Total paid$289K
24GClaims10,069
24DCodes billed20
24AFirst – last monthAug 2018 – Jan 2021
Compared with peers
Next to other Family Nurse Practitioner providers in Tennessee
Rank by total paid#61 of 687
Median peer was paid$15K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,831 | $43K | |
| 2019 | 5,484 | $172K | |
| 2020 | 2,740 | $75K | |
| 2021 | 14 | $0.00 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 51% | 4,097 | 3,736 | $148K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 17% | 418 | 200 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.9% | 1,444 | 1,362 | $17K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.5% | 636 | 595 | $16K |
| 80305 | 5.0% | 1,791 | 1,614 | $15K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 4.7% | 619 | 595 | $14K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.1% | 216 | 207 | $9K |
| 20552 | 1.9% | 205 | 198 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 99 | 92 | $5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.7% | 83 | 75 | $5K |
| 93923 | 1.2% | 65 | 31 | $4K | |
| 95923 | <1% | 32 | 31 | $2K |
8 more codes
| 81025 | <1% | 237 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 30 | $372.81 |
| 95924 | <1% | 13 | $214.76 | |
| 93040 | <1% | 32 | $212.16 | |
| 99406 | <1% | 13 | $75.13 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 12 | $72.21 |
| 82962 | <1% | 13 | $19.32 | |
| 36416 | <1% | 14 | $11.52 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.